Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma

Willem M C van Aalderen, Jonathan Grigg, Theresa W Guilbert, Nicolas Roche, Elliot Israel, Richard J Martin, Gene Colice, Dirkje S Postma, Elizabeth V Hillyer, Anne Burden, Victoria Thomas, Julie von Ziegenweidt, David Price

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)
5 Downloads (Pure)

Abstract

BACKGROUND: Because randomized controlled trials of established pediatric asthma therapies are expensive and difficult to perform, observational studies may fill gaps in the evidence base.

OBJECTIVES: To compare the effectiveness of representative small-particle inhaled corticosteroid (ICS) with that of standard size-particle ICS for children initiating or stepping up ICS therapy for asthma (analysis 1) and to compare the effectiveness of ICS dose step-up using small-particle ICS with adding long-acting β2-agonist (LABA) to the ICS (analysis 2).

METHODS: These historical matched cohort analyses drew on electronic medical records of children with asthma aged 5 to 11 years. Variables measured during 2 consecutive years (1 baseline year for confounder definition and 1 outcome year) included risk-domain asthma control (no hospital attendance for asthma, acute oral corticosteroids, or lower respiratory tract infection requiring antibiotics) and rate of severe exacerbations (asthma-related emergency, hospitalization, or oral corticosteroids).

RESULTS: In the initiation population (n = 797 in each cohort), children prescribed small-particle ICS versus standard size-particle ICS experienced greater odds of asthma control (adjusted odds ratio, 1.49; 95% CI, 1.10-2.02) and lower severe exacerbation rate (adjusted rate ratio, 0.56; 95% CI, 0.35-0.88). Step-up outcomes (n = 206 in each cohort) were also significantly better for small-particle ICS, with asthma control adjusted odds ratio of 2.22 (95% CI, 1.23-4.03) and exacerbations adjusted rate ratio of 0.49 (95% CI, 0.27-0.89). The number needed to treat with small-particle ICS to achieve 1 additional child with asthma control was 17 (95% CI, 9-107) for the initiation population and 5 (95% CI, 3-78) for the step-up population. Outcomes were not significantly different for stepped-up small-particle ICS dose versus ICS/LABA combination (n = 185 in each cohort).

CONCLUSIONS: Initiating or stepping up the ICS dose with small-particle ICS rather than with standard size-particle ICS is more effective and shows similar effectiveness to add-on LABA in childhood asthma.

Original languageEnglish
Pages (from-to)721-731
Number of pages11
JournalThe Journal of Allergy and Clinical Immunology: In Practice
Volume3
Issue number5
Early online date29 May 2015
DOIs
Publication statusPublished - Sep 2015

Keywords

  • asthma
  • childhood
  • small-particle beclomethasone
  • fluticasone
  • inhaled corticosteroid
  • long-acting β2-agonist
  • step-up therapy

Fingerprint Dive into the research topics of 'Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma'. Together they form a unique fingerprint.

Cite this